Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Cash Flow Statement
Cash Flow Statement
Day One Biopharmaceuticals Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||||||||
| Net Income |
(44)
|
(58)
|
(71)
|
(86)
|
(73)
|
(84)
|
(105)
|
(124)
|
(142)
|
(157)
|
(166)
|
(175)
|
(189)
|
(209)
|
(167)
|
(84)
|
(95)
|
(69)
|
(95)
|
(152)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
3
|
3
|
3
|
|
| Stock-Based Compensation |
1
|
1
|
3
|
9
|
13
|
19
|
22
|
26
|
27
|
30
|
34
|
35
|
39
|
43
|
46
|
48
|
48
|
48
|
46
|
44
|
|
| Other Non-Cash Items |
31
|
39
|
41
|
46
|
22
|
19
|
22
|
25
|
26
|
28
|
27
|
29
|
33
|
35
|
(65)
|
(10)
|
(11)
|
(14)
|
89
|
29
|
|
| Cash Taxes Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
7
|
6
|
|
| Change in Working Capital |
(0)
|
(2)
|
(3)
|
(1)
|
3
|
5
|
6
|
11
|
7
|
14
|
12
|
4
|
9
|
3
|
55
|
4
|
26
|
(7)
|
(60)
|
(0)
|
|
| Cash from Operating Activities |
(13)
N/A
|
(21)
-57%
|
(33)
-55%
|
(41)
-26%
|
(49)
-18%
|
(60)
-24%
|
(77)
-27%
|
(88)
-14%
|
(110)
-25%
|
(114)
-4%
|
(127)
-11%
|
(141)
-11%
|
(147)
-4%
|
(171)
-16%
|
(177)
-4%
|
(89)
+50%
|
(78)
+13%
|
(87)
-12%
|
(63)
+28%
|
(120)
-90%
|
|
| Investing Cash Flow | |||||||||||||||||||||
| Capital Expenditures |
(0)
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(17)
|
(18)
|
(19)
|
(23)
|
(6)
|
(5)
|
|
| Other Items |
0
|
(8)
|
(8)
|
(8)
|
(8)
|
0
|
(6)
|
(253)
|
(255)
|
(266)
|
(240)
|
96
|
129
|
229
|
243
|
87
|
(212)
|
(330)
|
(338)
|
(257)
|
|
| Cash from Investing Activities |
(0)
N/A
|
(8)
-8 789%
|
(8)
N/A
|
(8)
N/A
|
(8)
N/A
|
(0)
+100%
|
(6)
-29 950%
|
(253)
-4 107%
|
(255)
-1%
|
(266)
-4%
|
(240)
+10%
|
96
N/A
|
128
+34%
|
229
+78%
|
226
-1%
|
69
-69%
|
(231)
N/A
|
(353)
-53%
|
(344)
+3%
|
(262)
+24%
|
|
| Financing Cash Flow | |||||||||||||||||||||
| Net Issuance of Common Stock |
30
|
160
|
327
|
327
|
297
|
167
|
162
|
164
|
166
|
167
|
167
|
165
|
164
|
163
|
2
|
24
|
25
|
25
|
25
|
3
|
|
| Other |
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
178
|
178
|
0
|
0
|
0
|
|
| Cash from Financing Activities |
30
N/A
|
159
+430%
|
327
+106%
|
327
0%
|
297
-9%
|
168
-43%
|
162
-4%
|
164
+2%
|
166
+1%
|
167
+1%
|
167
+0%
|
165
-1%
|
164
-1%
|
163
-1%
|
2
-99%
|
202
+9 746%
|
203
+1%
|
203
0%
|
203
0%
|
3
-99%
|
|
| Change in Cash | |||||||||||||||||||||
| Net Change in Cash |
16
N/A
|
130
+691%
|
287
+121%
|
277
-3%
|
241
-13%
|
108
-55%
|
79
-27%
|
(176)
N/A
|
(199)
-13%
|
(213)
-7%
|
(200)
+6%
|
120
N/A
|
146
+21%
|
221
+52%
|
50
-77%
|
182
+260%
|
(106)
N/A
|
(237)
-124%
|
(204)
+14%
|
(379)
-86%
|
|
| Free Cash Flow | |||||||||||||||||||||
| Free Cash Flow |
(14)
N/A
|
(21)
-56%
|
(33)
-55%
|
(41)
-26%
|
(49)
-18%
|
(60)
-24%
|
(77)
-27%
|
(88)
-14%
|
(110)
-25%
|
(114)
-4%
|
(127)
-11%
|
(141)
-11%
|
(147)
-4%
|
(171)
-16%
|
(194)
-14%
|
(107)
+45%
|
(97)
+9%
|
(110)
-13%
|
(69)
+38%
|
(125)
-81%
|
|